Anti-Human Apolipoprotein A-IV, Mouse Monoclonal, (A4-18A3)
Anti-Human Apolipoprotein A-IV, Mouse Monoclonal, (A4-18A3)
DiagnoCine offers excellent APOLIPOPROTEIN antibodies to researchers studying human induced pluripotent stem cell, mitochondrial dysfunction, pathophysiology, genetic polymorphisms, metabolism, phospholipase A2 activity, cellular surface factor, angiotensin-converting enzyme, nitric oxide synthase activity, amyloidosis, epigenome/metabolome research, sialylation proteoforms, pathogenesis, and progression.
Human diseases include type 1 diabetes, Memory Deficit, hepatitis C virus, Alzheimer's Disease, Osteoporotic Fractures. endoplasmic reticulum stress, atherosclerotic lesions, cancer, multiple sclerosis, Toxic Hetero-oligomers, brain amyloid load, hypertriglyceridemic pancreatitis, Atherosclerosis, Schnauzers, coronary artery disease, psoriasis, cardiac amyloidosis, cardiovascular disease and hypertension, dementia, type 2 diabetes mellitus, toxicity in human neurons, cognitive impairment, atherothrombosis, familial hypobetalipoproteinemia, hyperlipidemia, Parkinson's disease, metabolic syndrome, coronary heart disease, and depression.
APOLIPOPROTEIN antibodies have excellent quality and this highly pure antibody can be adapted for Western Blots, ELISA, Immunohistochemistry, Immunofluorescence research with optimization.
General information
| Cat. No. | ：FNK-BML001 |
| Size | ：50 µg |
| Formulation | ：0.2 µm filtered PBSsolution containing 0.1% sodium azide |
| Label | ：Unlabeled |
| Specificity | ：This antibody has been selected for its ability to bind for human plasma apoA-IV and recombinant apoA-IVfrom CHO cells by western blot. |
| Class | ：IgG |
| Clone | ：A4-18A3 |
| Application | ：ELISA, Western Blot |
| Cross Reactivity | ：Human |
| Antigen | ：Human |
| Host Animal | ：Mouse |
| Purification | ：PAPu |
| Storage | ：IgG in PBS solution are stable for twelve months from the date of receipt when stored at-80˚C. Avoid repeated freeze-thaw cycles. |
Preparation
Produced in mice immunized with apolipoprotein A-IV (apo A-IV) purified from human plasma. Apo A-IV specific IgG was purified from mouse ascites fluid with a proteinA-Sepharose.
Additional Applications
Western Blot – This antibody can be used at 0.5 – 1.0 µg/mL with the appropriate secondary reagent to detect human plasma apo A-IV. The detection limit for purified apo A-IV and plasma sample is approximately 0.01 µg/lane and 0.1 µL, respectively, by SDS-PAGE and western blotting under reducing condition.
Sandwich ELISA – This antibody can be used as a capture antibody in a human apoA-IV ELISAin combination with the monoclonal detection antibody (Catalog #BML003). In general,using plates coated with 100 µL/well of5 µg/ml capture antibody (Catalog #BML001), in combination with 100 µL/well of 0.05 µg/ml detection antibody (Catalog #BML003), an ELISAfor sample volumes of 100 µL can be obtained. Titrate each preparation of the serum sample for standard preparation to arrive at the most suitable dose range.For this antibody pair, a two-fold dilution series starting at 200 ng/mL is suggested.
Optimal dilutions should be determined by each laboratory for each application.
Antigen Characterization
| Type | ：Glycoprotein |
| Application | ：ELISA, Western Blot, Platelet aggregation studies, Lipid metabolism research, Glucose homeostasis experiments, Anti-inflammatory studies, Cardiovascular disease research |
| Species | ：Human, rodent models |
| Recombinant | ：Not specified |
APOA4 in the Cell
- Synthesized in the small intestine and packaged into chylomicrons
- Secreted into intestinal lymph during fat absorption
- Associates with high-density lipoproteins (HDL) and chylomicron remnants in the bloodstream
- Involved in assembly and metabolism of triglyceride-rich lipoproteins
- Aids in efficient transport and processing of dietary fats
- Exhibits anti-oxidative and anti-inflammatory properties
- Protects cells against oxidative stress and inflammation
- Influences glucose metabolism by:
- Enhancing insulin secretion
- Moderating hepatic glucose production
- Potential therapeutic target for metabolic diseases (e.g., diabetes, obesity)
APOA4 in the Human Body
- Acts as an endogenous anti-inflammatory protein
- Suppresses activity of eosinophils and other effector cells
- Beneficial in allergic inflammation and asthma
- Protects against cardiovascular diseases by:
- Mediating reverse cholesterol transport
- Inhibiting platelet aggregation and thrombosis
- Reduces risk of heart attacks and strokes
- Regulates food intake as an acute satiation factor
- Influences peripheral and central mechanisms of appetite control
- Maintains energy balance
- Involved in glucose homeostasis
- Contributes to lipid metabolism
- Helps prevent conditions such as atherosclerosis and diabetes
Aliases for APOA4 Gene
References
- Xu, Xiaohong Ruby et al. “Apolipoprotein A-IV binds αIIbβ3 integrin and inhibits thrombosis.” Nature communications vol. 9,1 3608. 6 Sep. 2018, doi:10.1038/s41467-018-05806-0
- Obinata, Hideru et al. “Identification of ApoA4 as a sphingosine 1-phosphate chaperone in ApoM- and albumin-deficient mice.” Journal of lipid research vol. 60,11 (2019): 1912-1921. doi:10.1194/jlr.RA119000277
- Qu, J., Fourman, S., Fitzgerald, M. et al. Low-density lipoprotein receptor-related protein 1 (LRP1) is a novel receptor for apolipoprotein A4 (APOA4) in adipose tissue. Sci Rep 11, 13289 (2021). https://doi.org/10.1038/s41598-021-92711-0
- “Apolipoprotein A-IV/APOA4 Antibody (APOA4/3372) [HRP].” Novus Biologicals, www.novusbio.com/products/apolipoprotein-a-iv-apoa4-antibody-apoa4-3372_nbp3-08947h.
